133 related articles for article (PubMed ID: 4021540)
1. Simultaneous development of humoral and cellular tumor-specific immunity against L1210 mouse leukemia.
Kawashima K; Isobe K; Nagase F; Yokochi T; Nagura E; Hasegawa Y; Morishita H; Yamada K; Nakashima I
Leuk Res; 1985; 9(7):935-9. PubMed ID: 4021540
[TBL] [Abstract][Full Text] [Related]
2. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
Rahman SM; Kawashima K; Nakashima I; Nagase F
Cancer Res; 1988 Nov; 48(22):6450-4. PubMed ID: 3263189
[TBL] [Abstract][Full Text] [Related]
3. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
Rapp L; Fuji H
Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
[TBL] [Abstract][Full Text] [Related]
4. Common leukemia-associated antigen of DBA/2 mouse leukemia detected by tumor rejection and complement-dependent cytotoxicity assays.
Kawashima K; Takeyama H; Takahashi T; Kato Y; Watanabe E; Suzuki H; Minam S; Isobe K; Yamada K; Ito Y
Gan; 1979 Dec; 70(6):769-76. PubMed ID: 94022
[TBL] [Abstract][Full Text] [Related]
5. High-grade tumor-specific immunity induced by L1210 leukemia variants obtained from the culture of L1210 cells fused with Lesch-Nyhan fibroblasts.
Kawashima K; Nagura E; Watanabe E; Mizoguchi K; Saga S; Isobe K; Nakashima I; Yamada K; Oikawa T; Kojima K
Int J Cancer; 1983 Oct; 32(4):507-14. PubMed ID: 6618710
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of a unique tumor-associated surface antigen on L1210 leukemia cells recognized by semisyngeneic antisera.
Yokochi T; Kawashima K; Nakashima I; Nagase F; Isobe K; Nagura E; Yamada K; Miyadai T; Kimura Y
Cancer Res; 1987 Feb; 47(4):1006-9. PubMed ID: 3542198
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
Fuji H
Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline.
Testorelli C; Archetti YL; Aresca P; Del Vecchio L
Cancer Res; 1985 Nov; 45(11 Pt 1):5299-303. PubMed ID: 4053006
[TBL] [Abstract][Full Text] [Related]
9. Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells.
Nicolin A; Franco P; Testorelli C; Goldin A
Cancer Res; 1976 Jan; 36(1):222-7. PubMed ID: 1248001
[TBL] [Abstract][Full Text] [Related]
10. Vesicular stomatitis virus-infected L1210 murine leukemia cells: increased immunogenicity and altered surface antigens.
Wise KS
J Natl Cancer Inst; 1977 Jan; 58(1):83-90. PubMed ID: 189042
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a murine leukemia L1210-specific T-cell clone displaying novel in vivo anti-tumor activity.
Nagase F; Ueda K; Nakashima I; Kawashima K; Isobe K; Nagura E; Yamada K; Yokochi T; Hasegawa Y; Yoshida T
Int J Cancer; 1986 Dec; 38(6):907-14. PubMed ID: 3491792
[TBL] [Abstract][Full Text] [Related]
12. Induction of resistance to L1210 leukemia in BALB/c X DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A.
Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y
Cancer Res; 1977 Apr; 37(4):964-8. PubMed ID: 403001
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of murine leukemia antigen on L1210 parental and drug-resistant sublines.
Strzadala L; Opolski A; Radzikowski C; Mihich E
Cancer Res; 1981 Dec; 41(12 Pt 1):4934-7. PubMed ID: 7306993
[TBL] [Abstract][Full Text] [Related]
14. Growth and antigenic properties of a spontaneously regressing subline of leukemia L1210.
Koo PH
Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1371-6. PubMed ID: 6891934
[TBL] [Abstract][Full Text] [Related]
15. Immune rejection mechanisms in murine leukemia. I. Timing of tumor cell rejection process relative to the development of humoral and cell-mediated cytotoxic immune responses.
Ciavarra RP; Terres G
Int J Cancer; 1984 Nov; 34(5):681-8. PubMed ID: 6500745
[TBL] [Abstract][Full Text] [Related]
16. A significant role of proximity of HVJ-antigen in the generation of tumor immunity.
Kawashima K; Watanabe E; Kato Y; Suzuki H; Minami S; Isobe K; Ogura M; Nagura E; Yamada K
Gan; 1981 Dec; 72(6):955-8. PubMed ID: 6281118
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporin A/VP-16 produced immunity to L1210 leukemia: the participation of cytotoxic CD8 T-lymphocytes.
Slater LM; Sweet P; Stupecky M; Reynolds JT
Clin Immunol Immunopathol; 1995 Jun; 75(3):239-45. PubMed ID: 7768041
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a monoclonal antibody to L1210 leukaemia.
Testorelli C; Morelli S; Goldin A; Nicolin A
Br J Cancer; 1982 Mar; 45(3):395-402. PubMed ID: 7073934
[TBL] [Abstract][Full Text] [Related]
19. Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay.
Fuji H; Mihich E
Cancer Res; 1975 Apr; 35(4):946-52. PubMed ID: 1090366
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and amplifier cell production by tumor vaccines enhanced by concanavalin A.
Kataoka T; Oh-Hashi F; Sakurai Y
Gan; 1982 Apr; 73(2):193-205. PubMed ID: 6811360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
